Migraine

Findings for atogepant from the phase 3 PROGRESS study will form the basis of a submission by AbbVie to FDA for a label expansion in the US.

Consider migraine screening for all women aged 20 to 50 years, suggests Ailani; you'll likely find a majority of them have migraine. More pearls follow.

Migraine-specific preventive therapies should be in the primary care toolbox, according to headache specialist Jessica Ailani, MD.

Migraine headache specialist and researcher Jessica Ailani, MD, fully supports primary care as the setting for the majority of the treatment for the disease.

Lifetime use of opioids for migraine was found to be higher than for triptan medications. Try these 10 questions on other OVERCOME findings.

Findings on use of acute and preventive migraine therapy continue to reveal gaps with far more patients eligible than the proportions using either type.

Researchers identified over 120 regions connected to risk of migraine, of which 86 were previously unknown.

Researchers also found that women with migraine with aura had a higher risk of preeclampsia than those with migraine without aura.

Intranasal CGRP inhibitor zavegepant met coprimary regulatory endpoints in pivotal phase 3 trial in adults with migraine; FDA submission planned for Q1 2022.

The first vaccine against COVID-19, 2 new treatments for migraine, a novel topical agent for atopic dermatitis, and 4 more recently approved drugs of interest to primary care.